

(19)



(11)

EP 2 626 418 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 39/00 ^(2006.01) **A61K 35/17** ^(2015.01)
A61P 37/04 ^(2006.01) **A61P 43/00** ^(2006.01)
C07K 14/82 ^(2006.01) **C12N 5/0783** ^(2010.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:

24.03.2021 Bulletin 2021/12

(86) International application number:

PCT/JP2011/072874

(45) Date of publication and mention of the grant of the patent:

09.12.2020 Bulletin 2020/50

(87) International publication number:

WO 2012/046730 (12.04.2012 Gazette 2012/15)

(21) Application number: **11830662.0**

(22) Date of filing: **04.10.2011**

(54) METHOD FOR ACTIVATING HELPER T CELL

VERFAHREN ZUR AKTIVIERUNG VON T-HELPERZELLEN

PROCÉDÉ D'ACTIVATION D'UNE CELLULE T AUXILIAIRE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

- **GOTO, Yoshihiro**
Osaka-shi
Osaka 541-0045 (JP)

(30) Priority: **05.10.2010 JP 2010225806**

(74) Representative: **dompatent von Kreisler Selting Werner -**

Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln (DE)

(43) Date of publication of application: **14.08.2013 Bulletin 2013/33**

(73) Proprietor: **International Institute of Cancer Immunology, Inc.**
Suita-shi, Osaka 564-0053 (JP)

(56) References cited:

EP-A1- 1 696 027 EP-A1- 2 098 595
EP-A1- 2 119 778 WO-A1-2005/045027
WO-A1-2008/105462 WO-A1-2010/123065

(72) Inventors:

- **SUGIYAMA, Haruo**
Minoo-shi
Osaka 562-0036 (JP)
- **SOGO, Shinji**
Osaka-shi
Osaka 541-0045 (JP)
- **SATO, Masayoshi**
Osaka-shi
Osaka 541-0045 (JP)
- **KITAMOTO, Ryuki**
Osaka-shi
Osaka 541-0045 (JP)

- **MAY RENA J ET AL: "Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 15 Pt 1, 1 August 2007 (2007-08-01), pages 4547-4555, XP002544528, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-0708**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 626 418 B8

- C. LEHE ET AL: "The Wilms' Tumor Antigen Is a Novel Target for Human CD4+ Regulatory T Cells: Implications for Immunotherapy", **CANCER RESEARCH**, vol. 68, no. 15, 1 August 2008 (2008-08-01), pages 6350-6359, XP055082460, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0050
- FUJIKI F ET AL: "A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells", **MICROBIOLOGY AND IMMUNOLOGY, CENTER FOR ACADEMIC PUBLICATIONS JAPAN**, JP, vol. 52, no. 12, 1 December 2008 (2008-12-01), pages 591-600, XP002590600, ISSN: 0385-5600, DOI: 10.1111/J.1348-0421.2008.00080.X
- MUELLER L ET AL: "SYNTHETIC PEPTIDES DERIVED FROM THE WILMS' TUMOR 1 PROTEIN SENSITIZE HUMAN T LYMPHOCYTES TO RECOGNIZE CHRONIC MYELOGENOUS LEUKEMIA CELLS", **HEMATOLOGY JOURNAL, MCMILLAN, BASINGSTOKE, GB**, vol. 4, no. 1, 1 January 2003 (2003-01-01), pages 57-66, XP009044674, ISSN: 1466-4860, DOI: 10.1038/SJ.THJ.6200220
- KNIGHTS ASHLEY JOHN ET AL: "Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol", **CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE**, vol. 51, no. 5, 1 July 2002 (2002-07-01), pages 271-281, XP002473128, ISSN: 0340-7004, DOI: 10.1007/S00262-002-0278-2
- MAY R.J. ET AL.: 'Peptide epitopes from the Wilms' Tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells' **CLIN CANCER RES.** vol. 13, no. 15, 2007, pages 4547 - 4555, XP002544528
- FUJIKI F. ET AL.: 'A WT1 protein-derived, naturally processed 16-mer peptide, WT1322, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells' **MICROBIOL. IMMUNOL.** vol. 52, 2008, pages 591 - 600, XP002590600
- LEHE C. ET AL.: 'The Wilms' Tumor antigen is a novel target for human CD4+ regulatory T cells : Implications for immunotherapy' **CANCER RES.** vol. 68, 2008, pages 6350 - 6359, XP055082460
- KNIGHTS A.J. ET AL.: 'Prediction of an HLA-DR-binding peptide derived from Wilms' tumor 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol' **CANCER IMMUNOL. IMMUNOTHER.** vol. 51, 2002, pages 271 - 281, XP002473128
- MULLER L. ET AL.: 'Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells' **HEMATOL.J.** vol. 4, no. 1, 2003, pages 57 - 66, XP009044674